Morgan Stanley
LXEO icon

Morgan Stanley’s Lexeo Therapeutics LXEO Stock Holding History

Morgan Stanley’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.31M Buy
402,924
+262,743
+187% +$1.86M ﹤0.01% 4663
2025
Q4 		$1.39M Buy
140,181
+42,124
+43% +$384K ﹤0.01% 5015
2025
Q3 		$651K Buy
98,057
+13,276
+16% +$64.2K ﹤0.01% 5396
2025
Q2 		$341K Buy
84,781
+465
+0.6% +$1.53K ﹤0.01% 5636
2025
Q1 		$293K Buy
84,316
+9,488
+13% +$42K ﹤0.01% 5575
2024
Q4 		$492K Sell
74,828
-167,000
-69% -$1.32M ﹤0.01% 5422
2024
Q3 		$2.19M Buy
241,828
+229,165
+1,810% +$2.73M ﹤0.01% 4586
2024
Q2 		$203K Sell
12,663
-1,281
-9% -$18.6K ﹤0.01% 5668
2024
Q1 		$219K Sell
13,944
-5,032
-27% -$78.7K ﹤0.01% 5705
2023
Q4 		$255K Buy
+18,976
New +$236K ﹤0.01% 5856

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley's LXEO Position: Q1 2026 in Review

Morgan Stanley increased its Lexeo Therapeutics (LXEO) stake by 187% in Q1 2026, buying an estimated $1.86M and bringing the position to 402,924 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4663.

Morgan Stanley first reported a position in LXEO in Q4 2023 and has held it in 10 quarters since. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Morgan Stanley held 402,924 shares of Lexeo Therapeutics worth $2.31M as of Q1 2026.
  • Morgan Stanley bought 262,743 Lexeo Therapeutics shares in Q1 2026, an estimated $1.86M.
  • Lexeo Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4663 holding.
  • Morgan Stanley first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.